In the last decade, there has been a significant increase in the prevalence of neurodegenerative diseases (NDD) in the United States, affecting approximately 10.5 million individuals. This number is predicted to triple in the next 30 years.¹ However, in comparison to other disease areas such as oncology, the approval of NDD drugs has been relatively limited. Our team has explored the NDD drug development ecosystem from three perspectives: stakeholders, funding, and policy. This article summarizes our key findings and presents a case study to suggest that the scarcity of new drug development may be attributable to insufficient basic scientific research. Finally, we outline our objectives for the upcoming semester.

As highlighted in our initial blog post, the neurodegenerative disease (NDD) drug development space has seen little progress compared to other disease areas such as cancer and immunology. A number of factors contribute to a lack of curative or disease-altering therapies addressing NDD including a poor understanding of the pathophysiology of most NDDs and historically lower investment as opposed to other disease areas. However, the use of policy instruments has the potential to drive progress and improve NDD drug development. This article introduces our research on the impact of key policies on NDD drug development. It also presents our initial findings on the effectiveness of current policies and identifies areas where further action is needed.

*This blog is part of a series titled TAPP for Neurodegenerative Diseases Drug Discovery: Mapping the ecosystem